Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC

臺大醫院;臺大醫院-腫瘤醫學部;臺大醫學院;臺大醫學院-腫瘤醫學研究所;Mok, T.T.MokSaijo, N.N.SaijoThongprasert, S.S.ThongprasertYang, J. C. -H.J. C. -H.YangWu, Y. -L.Y. -L.WuYoung, H.H.YoungHaddad, V.V.HaddadJiang, H.H.JiangFukuoka, M.M.Fukuoka2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280156Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC